Semaglutide's drug class, and why it matters for weight loss

The common misconception: semaglutide is not a stimulant or appetite suppressant in the traditional sense

Many people searching for information on the semaglutide drug class arrive expecting something like a stimulant, a medicine that fires up metabolism or chemically suppresses hunger signals in the brain through an adrenergic pathway. That picture is wrong, and the difference matters clinically.

Semaglutide is a GLP-1 receptor agonist: a synthetic analogue of glucagon-like peptide-1, a hormone your gut releases after you eat. It works by binding to GLP-1 receptors in the pancreas, gut wall and brain, not by stimulating the central nervous system the way older weight-loss medicines did. The practical result is slower gastric emptying (food sits in the stomach longer), a stronger satiety signal reaching the brain, and (in people with type 2 diabetes) improved insulin secretion. These are biological mechanisms your body already uses; semaglutide amplifies them.

Understanding what semaglutide actually does at receptor level also explains the titration schedule: doses start low precisely because the GI tract needs time to adapt to a stronger signal. Starting at 0.25 mg and stepping up gradually is not a formality, it is built into how the class works. You can read more about the medicine itself on our semaglutide overview page.

The NHS medicines information for semaglutide covers the mechanism in plain language and is a good reference point alongside anything a prescriber tells you: NHS, semaglutide.

What drug class is Wegovy, and how does the class define the prescription?

Wegovy is the weight-management brand of semaglutide. In terms of drug class, Wegovy sits squarely in the GLP-1 receptor agonist family, the same class as liraglutide (Saxenda), dulaglutide and, in a related dual-pathway variant, tirzepatide. The class as a whole has reshaped how clinicians think about obesity treatment over the past decade, shifting it from a willpower conversation to a pharmacological one grounded in endocrinology.

For prescribers, the class membership of Wegovy has direct implications. GLP-1 receptor agonists are not licensed for cosmetic weight loss; they are indicated for adults with a BMI of 30 or above, or 27 to 29.9 alongside a weight-related condition such as high blood pressure or type 2 diabetes. NICE's recommendation for semaglutide (TA875) goes further, restricting NHS access to specialist weight management services for a maximum of two years, a condition that flows partly from the class's profile in long-term trials. NICE technology appraisal TA875 sets out those criteria in full.

Privately, the licensing thresholds apply but the NHS specialist-service restriction does not, which is why a regulated online pharmacy can offer a route that does not require a hospital referral. The Wegovy page on this site explains the eligibility picture in more detail. If you want to compare the treatment options side by side, our weight-loss treatments overview is a useful starting point.

GLP-1 class side effects: the pattern, not the panic

The side-effect profile of GLP-1 receptor agonists is consistent across the class because it follows directly from the mechanism. Slowing gastric emptying is the therapeutic goal, and it is also the reason the most common effects are gastrointestinal: nausea, loose stools or constipation, indigestion, and burping. These tend to be most noticeable in the first week or two at a new dose, then settle for most people as the gut adapts.

Less common but important: the MHRA has highlighted acute pancreatitis as a known infrequent risk across GLP-1 medicines. Severe stomach pain that spreads to the back, with or without vomiting, warrants urgent medical attention, not a wait-and-see approach. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk is the right place to report any suspected side effect.

Because oral and injectable semaglutide share the same drug class, the side-effect pattern is broadly similar regardless of formulation. The tablet version (approved by the MHRA in June 2026 and stored at room temperature, no fridge required) suits people who prefer not to inject, though GI effects in trials were slightly more frequent with the oral route. Keep the tablet in your bag or on the counter where you'll see it first thing; the dosing instruction is an empty-stomach, first-in-the-morning routine. Details on the class-of-drugs comparison page explain how this plays out across formulations.

How semaglutide's class compares to the only other licensed weight-loss medicine in this bracket

Tirzepatide (Mounjaro) is often discussed alongside semaglutide, and while the two are frequently grouped together in conversation, they occupy different drug classes. Semaglutide activates one receptor pathway, GLP-1. Tirzepatide activates two: GLP-1 and GIP. That dual mechanism is the pharmacological reason the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, found greater average weight loss with tirzepatide than with semaglutide 2.4 mg over 72 weeks.

Neither result means one medicine is universally better. The drug class that suits you depends on your health history, how your body responds to the mechanism, any other medicines you take, and whether you'd prefer an injection or a tablet. A prescriber works through those factors; a drug-class article cannot. The semaglutide medication class page explores the distinction between GLP-1 and dual-agonist classes in more depth, and our page on newer semaglutide formulations covers what has changed since the original approval.

If you have questions about which option might suit your situation, speaking to a prescriber is the only way to get a proper answer. At nume, a GPhC-registered Independent Prescriber reads every consultation (a real clinician, not automated decision software) and the review happens the same day you apply. Start your free consultation to speak to our prescribers.